Efficacy of Pentoxifylline on Chronic Kidney Disease
To study whether pentoxifylline has additive renoprotective effect in patients taking...
Brief Summary
Official Title: “Phase 4 Study of the Efficacy of Pentoxifylline in Patients With Chronic Kidney Disease Receiving Angiotensin Receptor Blockade”
To study whether pentoxifylline has additive renoprotective effect in patients taking ARB
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
- Study Primary Completion Date: July 2006
Detailed Clinical Trial Description
In patients with CKD and serum creatinine 1.3~6.0 md/gl, having taken losartan 100 mg/day for at least 3 months, with stable renal function, will be recruited to a randomized open-label trial. Patients taking pentoxifylline or not will be compared for their spot urinary proteinuria, estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone concentration between groups in a 2-year study. Add-on pentoxifylline in control group in the same dose as in treat group will be performed to observe the renoprotective effect if any protective potential is demonstrated in the end of maintenance 12 months.
Intervention(s) in this Clinical Trial
- Drug: pentoxifylline (drug)
Outcome Measures for this Clinical Trial
Primary Measures
- spot urinary proteinuria between groups
Secondary Measures
- estimated glomerular filtration, spot urine tumor necrosis factor-α/creatinine ratio, spot urine monocyte-chemoattractant protein-1/creatinine, and aldosterone concentration between groups.
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Chronic kidney disease with serum creatinine 1.3~6.0 mg/dl
Exclusion Criteria:
- History of allergy to pentoxifylline
- Females are nursing or pregnant
- Obstructive uropathy
- Unable to stop chronic immunosuppressive therapy, NSAID
- Congestive heart failure (New York Heart Association functional class III or IV)
- Unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, within the past 6 months prior to signing the informed consent form
- Cerebral hemorrhage within the past 6 months prior to signing the informed consent form
- Retinal hemorrhage within the past 6 months prior to signing the informed consent form
- Known or suspected secondary hypertension (e.g., primary aldosteronism, renovascular hypertension, pheochromocytoma)
- Severe uncontrolled hypertension with SBP > 220 mmHg and/or DBP > 115 mmHg
- Hepatic dysfunction as defined by the following laboratory parameters: ALT or AST > 2 times the upper limit of the normal range
- Biliary obstructive disorders (e.g. cholestasis)
- Active malignancy
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 70 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: National Taiwan University Hospital Other
Overall Clinical Trial Officials and Contacts
Tun-Jun Tsai, MD, PhD Principal Investigator National Taiwan University Hosptial
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00155246
Study ID Number: 930202
ClinicalTrials.gov Identifier: NCT00155246
Health Authority: Taiwan: Department of Health
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00155246
